Digital PCR can reliably determine if chronic myeloid leukemia patients in remission can successfully discontinue drug treatment

Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for which patients chronic drug treatment could potentially be discontinued. This transcript that is unique for CML is more sensitive and accurate than the current standard, real-time quantitative PCR (RT-qPCR), for detecting ultralow levels of residual leukemic disease.

from Top Health News -- ScienceDaily https://ift.tt/F0ufxPn